Mallinckrodt plc announced the presentation of 11 scientific abstracts with findings from the latest clinical and health economics research with TERLIVAZ (terlipressin) for injection for adult patients with hepatorenal Syndrome (HRS) with rapid reduction in kidney function1 during the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting, taking place November 10-14, 2023 in Boston, MA. Included among Mallinckrodt's breadth of data for adults with HRS with rapid reduction in kidney function are three oral presentations and one Poster of Distinction detailing research of clinical outcomes with TERLIVAZ2,3,4 and real-world health economics outcomes for TERLIVAZ-treated patients with comorbidities. TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with HRS with rapidly reduction in kidney function, an acute and life-threatening condition requiring hospitalization.

HRS involving rapid reduction in kidney function is estimated to affect more than 35,000 Americans annually and rates of HRS hospitalizations are increasing. Please see Limitation of Use and Important Safety Information, including Boxed Warning, below. Highlights of Mallinckrodt's 11 scientific presentations at the AASLD 2023 Liver Meeting include: Three Oral Presentations: Findings from a pooled analysis of the three largest-ever prospective studies to assess the safety and efficacy of TERLIVAZ in patients with HRS type 1 (HRS-1) in the U.S. and Canada (CONFIRM, REVERSE, and OT-0401) evaluating the impact of mean arterial pressure on HRS reversal from baseline to end of treatment with TERLIVAZ (Abstract #224).

Health economics outcomes from a decision-analytic model projecting the benefit of TERLIVAZ treatment among patients with alcohol-related cirrhosis and HRS (Abstract #80). An analysis of the clinical outcomes associated with concomitant albumin dosing with TERLIVAZ for the treatment of HRS-acute kidney injury (HRS-AKI) (Abstract #211). One AASLD Poster of Distinction: Results from a post hoc analysis of the CONFIRM, REVERSE), and OT-0401 trials assessing the relationship between mean arterial pressure and TERLIVAZ in HRS-AKI reversal (Abstract #3052-A).